AIFF FIREFLY NEUROSCIENCE INC

Firefly Neuroscience to Participate in the 8th Annual Florida Capital Event

Firefly Neuroscience to Participate in the 8th Annual Florida Capital Event

TORONTO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced that management will participate in the Capital Event Management Conference being held at the JW Marriott Miami in Aventura, Florida on November 22-24, 2024.

To schedule a one-on-one investor meeting with management, please contact your representatives at CEM or email KCSA Strategic Communications at .

About CEM

CEM curates exclusive live events and virtual meetings where issuers and investors have unique opportunities to connect 1:1 and build lasting relationships. Since 2011 CEM has provided issuers a forum to raise capital, gain market support, save time & money, and build relationships with leading North American small cap investors.

About Firefly

Firefly (NASDAQ: AIFF) is an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders. Firefly’s FDA-510(k) cleared Brain Network Analytics (BNA™) technology revolutionizes diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD. Over the past 15 years, Firefly has built a comprehensive database of brain wave tests, securing patent protection, and achieving FDA clearance. The Company is now launching BNA™ commercially, targeting pharmaceutical companies engaged in drug research and clinical trials, as well as medical practitioners for clinical use.

Brain Network Analytics was developed using artificial intelligence and machine learning on Firefly’s extensive proprietary database of standardized, high-definition longitudinal electroencephalograms (EEGs) of over 17,000 patients representing twelve disorders, as well as clinically normal patients. BNA™, in conjunction with an FDA-cleared EEG system, can provide clinicians with comprehensive insights into brain function. These insights can enhance a clinician’s ability to accurately diagnose mental and cognitive disorders and to evaluate what therapy and/or drug is best suited to optimize a patient’s outcome.

Please visit  for more information.

Investor Contact

KCSA Strategic Communications

Valter Pinto or Jack Perkins

(212) 896-1254

Media Contact

KCSA Strategic Communications

Raquel Cona, Vice President

(516) 779-2630



EN
06/11/2024

Underlying

AIFFFIREFLY NEUROSCIENCE INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on FIREFLY NEUROSCIENCE INC

 PRESS RELEASE
Free
AIFF FIREFLY NEUROSC...

Firefly Neuroscience Successfully Deploys NVIDIA L40S GPU Acceleration...

Firefly Neuroscience Successfully Deploys NVIDIA L40S GPU Acceleration to Power Next-Gen ‘CLEAR’ Platform – Unlocks exciting new AI-driven brain biomarker discovery and advancement capabilities – – Substantial processing speed gains while maintaining high signal quality standards – – Comes just months after Firefly its acceptance into the NVIDIA Connect Program – KENMORE, Wash. and NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that impr...

14h / 41m 1 EN
 PRESS RELEASE
Free
AIFF FIREFLY NEUROSC...

Firefly Inks Latest Commercial Agreement for Use of its FDA-Cleared BN...

Firefly Inks Latest Commercial Agreement for Use of its FDA-Cleared BNA™ Platform in Groundbreaking Precision Neuroscience Research – Institute of Human Genetics at Heidelberg University Hospital ongoing EEG biomarker study on 15q13.3 CNVs – – Collaboration aims to uncover novel insights into the brain’s functional architecture in rare genetic conditions – – Building and growing a license business is an increasingly important pillar of Firefly’s commercial strategy – KENMORE, N.Y., July 14, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF),...

July 14, 2025 1 EN
 PRESS RELEASE
Free
AIFF FIREFLY NEUROSC...

Firefly Neuroscience to be Added to the Russell Microcap® Index

Firefly Neuroscience to be Added to the Russell Microcap® Index – Comes less than a year after listing on Nasdaq – KENMORE, N.Y., June 23, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced that it will be added to the Russell Microcap® Index as part of this year’s reconstitution. The additions will be made effective after the U.S. market opens on June 30, 2025. Russ...

June 23, 2025 1 EN
 PRESS RELEASE
Free
AIFF FIREFLY NEUROSC...

Firefly Neuroscience Researchers Uncover Powerful New Way of Objective...

Firefly Neuroscience Researchers Uncover Powerful New Way of Objectively Measuring SCD, MCI, and Dementia in Alzheimer’s Patients – Research supports combined use of EEG/ERP and vMRI for accurate differential diagnosis of SCD, MCI and dementia – – Also highlights that low-cost and off-based EEG/ERP alone also delivered reasonably accurate predictions of cognitive impairment typology – – Underscores the value of recent Evoke acquisition that builds upon Firefly's FDA-cleared BNA™ AI platform and unique integrated normative reference group – – It’s well accepted that earlier dementi...

June 20, 2025 1 EN
 PRESS RELEASE
Free
AIFF FIREFLY NEUROSC...

Correction From Source: Firefly Neuroscience Achieves Multi-Fold Datab...

Correction From Source: Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc. A correction from source is being issued with respect to the press release titled, Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc., released on May 5, 2025 at 8:00 am ET. Please note, the correct form of payment of the potential Evoke investors’ earn-out is in Firefly’s common stock. The complete corrected press release fol...

May 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch